
price data provid thomson reuter
number may add due round
remain outperform rate share increment cautiou
guidanc reduct surpris entireti biotech sector
deal impact step back agre manag
strategi find way diversifi exist complement franchis busi
simpli put right move said headwind creat
challeng environ undertak intens educ outreach
campaign andexxa make us wonder right asset
lower complement franchis estim
adjust item tie updat guidanc deriv
target share previous await sign global reopen
acknowledg mark challeng period
beat guidanc updat overshadow result report
revenu beat non-gaap ep beat period
howev manag lower revenu guidanc focu larg
center growth outlook note manag lower total
revenu guidanc rang midpoint
fluid situat impact manifest manag note
biggest impact product franchis current center new patient
side volum declin time initi therapi compliance/
persist also consider keep mind howev vari
diseas set lastli manag also note price impact like
manifest though like lag effect pull-forward ultomiri
dose amplifi impact outsid anticip potenti shift
underli payer mix see effort ultomiri on-bodi
sc injector data import competit differenti look
market entri check note unlik
impact due soliri biosimilar product
model updat cut revenu estim lower revenu
estim market product like see biggest impact
re-acceler manifest later year deriv
declin market share cut incorpor increment price eros
blend soliris/ultomiri price assumpt total revenu
move slightli ahead high-end
updat guidanc rang adjust sg expens tie
updat guidanc deriv price target appli multipl
previous non-gaap ep estim discount back
remain outperform rate headwind like transient
wonder potenti impact futur flare up variou
project model diverg forecast see link bottom line
remain outperform rate share acknowledg come month
like challeng
wedbush secur seek busi compani cover
research report thu investor awar firm may
conflict interest could affect object report investor
consid report singl factor make invest decis
pleas see page report analyst certif import
diversif strategi right approach wild card
remain outperform rate share increment cautiou guidanc
reduct surpris entireti biotech sector deal impact
step back agre manag strategi find way diversifi exist
complement franchis busi simpli put right move said
headwind creat challeng environ undertak intens educ
outreach campaign andexxa make us wonder right asset lower
complement franchis estim adjust item
tie updat guidanc deriv target share previous
await sign global reopen acknowledg mark challeng period
takeaway report total revenu beat consensu
ws estim likewis non-gaap ep beat consensu ws estim
figur illustr actual result quarter compar ws
overshadow result manag lower revenu ep
guidanc see figur total revenu guidanc decreas
mid-point previou guidanc midpoint
note alexion financi guidanc base current foreign exchang rate net hedg activ
includ effect acquisit licens strateg agreement intang asset
impair litig charg chang fair valu conting consider gain loss relat
strateg equiti invest restructur relat activ outsid previous announc activ
may occur issuanc present updat guidanc exclud financi impact
recent announc agreement acquir portola reconcili non- financi
guidanc avail www alexion com
continu remain fluid situat manag note disrupt
product franchis center new patient start well time initi therapi
compliance/persist expect vari diseas set price impact like
manifest lag effect ultomiri transit like pull forward instanc
howev neg impact overal price discount versu soliri
pnh ahu initi year
pipelin put take
manag provid updat pipelin program remain fluid
situat term affect trial enrol execut highlight key program
remain track see
ultomiri on-bodi sc manag affirm phase readout once-weekli on-
bodi subcutan inject continu track think
import competit differenti look market entri
phase studi wilson diseas fulli enrol
manag assert studi track top-lin readout recal studi
incorpor subject maintain primari endpoint percentag chang
baselin day week non-ceruloplasmin-bound copper level compar
standard care copper control
lower revenu estim market product like see
biggest impact re-acceler manifest later year deriv
declin market share cut incorpor increment price eros blend
soliris/ultomiri price assumpt total revenu move
slightli ahead high-end updat guidanc rang adjust
sg expens tie updat guidanc deriv price target appli
multipl previous non-gaap ep estim discount back per year
headwind like transient wonder potenti impact futur
flare up variou project model diverg forecast see link bottom line
remain outperform rate share acknowledg come month like
incom statement ms
good sold
 expens revenu
sg expens revenu
target deriv multipl ep discount back discount vs large-cap
consensu ep due current headwind
risk attain price rate
clinic data emerg clinic studi significantli impact share either posit neg direct
regulatori alexion employ acceler strategi gain approv market product regul may requir
addit data could alter requir approv necessit addit longer studi failur gain product
label lack certain featur could limit alexion abil gain traction market
commerci failur execut commerci inabl meet/exce expect impact share
competit updat competitor may posit neg impact share relev competitor includ compani
novarti regeneron achillion competitor like emerg time
generic/biosimilar entri new gener biosimilar agent may put pressur alexion exist market product
limit compani abil realiz increas price
laura chico certifi view express report accur reflect person opinion
directli indirectli receiv compens payment connect specif recommend view contain
report
outperform expect total return stock outperform rel median total return analyst analyst
team coverag univers next month
neutral expect total return stock perform in-lin median total return analyst analyst team
coverag univers next month
under-perform expect total return stock under-perform rel median total return analyst
analyst team coverag univers next month
invest rate base expect perform stock base anticip total return price target rel
stock analyst coverag univers analyst team coverag
may
may
distribut rate requir finra rule howev ws stock rate outperform neutral under-perform
close conform buy hold sell respect pleas note howev definit ws stock rate
rel basi
analyst respons prepar research report receiv compens base specif invest bank activ
analyst receiv compens base upon variou factor includ ws total revenu portion gener
ws invest bank activ
